Akari Therapeutics

Historical price data

Akari Therapeutics' mission is to develop and commercialize nomacopan, a first-in-class bispecific inhibitor of C5 and LTB4, for rare inflammatory disorders. Its primary achievement is advancing nomacopan into late-stage clinical trials for hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid. The company's strategy is intensely focused, dedicating all resources to generating pivotal clinical data to demonstrate proof-of-concept and unlock significant value. As a micro-cap biotech, its near-term fate is inextricably linked to the success of its lead program.

A platform based on bispecific recombinant protein inhibitors designed to simultaneously target the complement system (C5) and the leukotriene pathway (LTB4) to treat inflammatory diseases.

Faces competition from off-label use of approved C5 inhibitors (e.g., eculizumab) in HSCT-TMA and from corticosteroids/other biologics in Bullous Pemphigoid. Its key differentiator is nomacopan's dual C5/LTB4 inhibition, but it competes against larger companies with greater resources.